KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Glycaemic Control According to the Final Insulin Dose Using an Innovative Fixed-Dose Titration of Weekly Insulin Efsitora in Insulin-Naïve Type 2 Diabetes.

Lisa Connery, Julio Rosenstock, Neda Rasouli, Alice Y Y Cheng, Andreas Liebl, Qianqian Wang, Vitoria Pires, Alastair Knights, Michael B Davidson, Christopher J Child

Diabetes Obes Metab 28(7) 6217-6224

PMID42070786
PMCIDPMC13243980
DOI10.1111/dom.70814
发表日期2026-05-03
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:森林图/亚组分析图;FIGURE 3:森林图/亚组分析图。
摘要

摘要

AIMS: In the QWINT-1 phase 3 Trial, once-weekly insulin efsitora alfa (efsitora) administered using an innovative fixed-dose regimen demonstrated noninferior HbA1c reduction versus once-daily insulin glargine U100 (glargine) over 52 weeks in insulin-naïve adults with type 2 diabetes. This report focuses on baseline characteristics and clinical outcomes of efsitora-treated participants based on their insulin dose at Week 52 (N = 303). METHODS: Efsitora was dosed using a fixed-dose titration regimen with 100, 150, 250 and 400 U fixed-doses titrated as needed every 4 weeks to achieve fasting blood glucose (FBG) of 80-130 mg/dL (4.4-7.2 mmol/L). Participants not at target FBG on the 400 U fixed-dose after ≥ 4 weeks transitioned to flexible dosing using an efsitora multi-dose pen. Glargine was administered using a multi-dose pen and titrated weekly to the same target. Analyses assessed clinical characteristics and glycaemic outcomes by efsitora dose at Week 52, and hypoglycaemia after fixed-dose increases. RESULTS: Participants requiring higher Week 52 efsitora doses had greater baseline weight, HbA1c and fasting glucose, and more were male. Most participants (76%) remained on a fixed efsitora dose, and the majority established their final dose by Week 16. All efsitora fixed-doses resulted in robust HbA1c lowering, with mean final HbA1c < 7.0%. Based on events within 4-week periods after an efsitora fixed-dose increase, estimated rates of combined Level 2 and 3 hypoglycaemia were < 0.5 events/year. CONCLUSIONS: In QWINT-1, the innovative fixed-dose efsitora simple titration resulted in effective HbA1c lowering for all fixed doses. Rates of clinically meaningful hypoglycaemia were low after fixed-dose increases.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Proportion of participants treated with efsitora using each fixed‐dose and the multi‐dose pen throughout the study. Width of the flow between doses and bars at timepoint are proportional to the number of participants affected. Open bars represent proportion of missing dose information at timepoint. † Based on available insulin dose information at Week 52.
非 KM Figure
FIGURE 2FIGURE 2 HbA1c and FBG from baseline to Week 52. (A and B) Values by efsitora dose subgroups at Week 52. Only those with non‐missing dose information at Week 52 were included. Data are presented as mean. (C and D) Values for participants assigned to efsitora versus glargine. Data are presented as least‐squares mean from a mixed model for repeated measures. FBG = fasting blood glucose; HbA1c = glycosylated haemoglobin.
非 KM Figure
FIGURE 3FIGURE 3 Proportion of participants achieving HbA1c < 7.0% and ≤ 6.5% at Week 52. (A and B) Estimated percentages of participants by efsitora dose subgroups determined by the participants' efsitora dose at Week 52; only those with non‐missing dose information at Week 52 were included. (C and D) Estimated percentages of participants assigned to efsitora versus glargine. Missing HbA1c values at Week 52 are imputed by the return‐to‐baseline multiple imputation approach. HbA1c = glycosylated haemoglobin.
非 KM Figure